基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 生物化工 抗体 ATIC antibody ATIC抗体
  • ATIC抗体
  • ATIC抗体
  • ATIC抗体

1/3

ATIC抗体

Rabbit Polyclonal ATIC Antibody
询价 20μl 起订
50μl 起订
100μl 起订
湖北 更新日期:2025-05-11

湖北瑞和宁生物科技有限公司

VIP1年
联系人:周经理
电话:027-19371278702拨打
手机:18008634902 拨打
邮箱:19384116026@163.com

产品详情:

中文名称:
ATIC抗体
英文名称:
Rabbit Polyclonal ATIC Antibody
品牌:
艾普蒂
产地:
武汉
保存条件:
Stored at -20°C for 2118 year. Avoid repeated freeze / thaw cycles.
产品类别:
抗体
重组:
应用:
WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性:
Human,Mouse,Rat
宿主:
Rabbit
偶联物:
靶点:
ATIC

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC1/25-1/100 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM咨询技术 Human,Mouse,Rat
Elisa1/1000-1/2000 Human,Mouse,Rat
   

产品详情

AliasesPURH; AICAR; AICARFT; IMPCHASE; HEL-S-70p
WB Predicted band size65 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Mouse, Rat
ImmunogenFusion protein of human ATIC
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

  •  

     

       Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: 231 cell, Primary antibody: P01978(ATIC Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human brain tissue using P01978(ATIC Antibody) at dilution 1/25. (Original magnification: ×200)    


           

参考文献

以下是3篇与ATIC抗体相关的研究文献概览(注:文献信息为模拟示例,实际引用需核实原文):

---

1. **文献名称**:*Autoantibodies against ATIC in patients with dermatomyositis: Clinical associations and diagnostic implications*

**作者**:Hirakata M, et al.

**摘要**:研究报道在皮肌炎患者血清中发现抗ATIC自身抗体,该抗体与间质性肺病(ILD)和关节炎等临床特征显著相关,提示其可能作为疾病亚型分型或预后的潜在生物标志物。

---

2. **文献名称**:*ATIC overexpression as a therapeutic target in hepatocellular carcinoma: Development of monoclonal antibodies for detection*

**作者**:Nakamura T, et al.

**摘要**:研究证实肝癌组织中ATIC蛋白表达上调,并通过开发特异性单克隆抗体验证其作为肿瘤治疗靶点的潜力,抗体用于体外诊断和药物疗效评估。

---

3. **文献名称**:*Structural characterization of human ATIC and antibody-based inhibition studies in cancer cells*

**作者**:Smith J, et al.

**摘要**:解析人源ATIC的晶体结构,并利用抗体阻断其酶活性,发现可抑制肿瘤细胞增殖,为靶向嘌呤合成的抗癌策略提供理论依据。

---

**提示**:建议通过PubMed或Google Scholar搜索关键词“ATIC antibody”“anti-ATIC autoantibody”或结合疾病名称(如“dermatomyositis”“cancer”)获取真实文献数据。

       

背景信息

Anti-ATIC antibodies target the enzyme Aminoimidazole Carboxamide Ribonucleotide Transformylase/IMP Cyclohydrolase (ATIC), a bifunctional protein critical in the *de novo* purine biosynthesis pathway. ATIC catalyzes the final two steps of this pathway, converting 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) to inosine monophosphate (IMP), which is essential for DNA/RNA synthesis and cellular proliferation. Dysregulation of ATIC has been implicated in cancer, autoimmune disorders, and inflammatory diseases.

In autoimmune contexts, anti-ATIC antibodies are primarily associated with dermatomyositis (DM), particularly in patients with anti-synthetase syndrome. These autoantibodies are detected in ~1–4% of DM cases and often correlate with specific clinical features like interstitial lung disease and Raynaud’s phenomenon. Their presence aids in disease subtyping and prognosis.

Research suggests ATIC may act as an autoantigen due to its overexpression or aberrant exposure during cellular stress, triggering immune recognition. Anti-ATIC antibodies are detected via immunoprecipitation, ELISA, or line immunoassays. Beyond diagnostics, studying these antibodies provides insights into disease mechanisms, such as interferon pathway activation in myositis.

Therapeutic strategies targeting ATIC (e.g., methotrexate analogs) are explored in cancer, while in autoimmunity, understanding antibody-antigen interactions may inform biomarker development or immune-modulating therapies. However, the exact pathogenic role of anti-ATIC antibodies remains under investigation, highlighting their dual significance in cellular metabolism and immune dysregulation.

       
ATIC抗体;ATIC;ATIC Antibody;

公司简介

湖北瑞和宁生物科技有限公司研究创新能力, 拥有完整、科学、质量管理体系。并不断致力于技术创新,产品创新和管理创新,赢得了国内外广大用户的信任。

成立日期 (2年)
注册资本 50万(元)
员工人数 1-10人
年营业额 ¥ 100万以内
经营模式 贸易,工厂,试剂,定制,服务
主营行业 中间体,化学试剂

ATIC抗体相关厂家报价

  • 抗CRF抗体
  • 抗CRF抗体
  • 维百奥(北京)生物科技有限公司 VIP
  • 2025-12-29
  • 询价
内容声明
拨打电话 立即询价